Ken Griffin Hutchmed (China) LTD Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$16.36 - $21.78 $17,996 - $23,958	1,100 Added 40.74%	3,800 $65,000
Q1 2024 May 15, 2024	BUY	$12.08 - $18.56 $4,832 - $7,423	400 Added 17.39%	2,700 $45,000
Q4 2023 Feb 14, 2024	SELL	$16.25 - $20.23 $42,250 - $52,598	-2,600 Reduced 53.06%	2,300 $41,000
Q3 2023 Nov 14, 2023	BUY	$11.85 - $16.95 $17,775 - $25,425	1,500 Added 44.12%	4,900 $83,000
Q2 2023 Aug 14, 2023	SELL	$10.78 - $17.73 $25,872 - $42,552	-2,400 Reduced 41.38%	3,400 $40,000
Q1 2023 May 15, 2023	BUY	$13.02 - $19.87 $66,402 - $101,337	5,100 Added 728.57%	5,800 $75,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $15.51 $5,355 - $10,857	700 New	700 $10,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.